Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection

Clinical Infectious Diseases

Volumn 41, Issue 6, 2005, Pages 883-890

  Arnedo Valero, M ^a   García, Felipe ^a,b   Gil, C ^a   Guila, T ^a   Fumero, E ^a   Castro, P ^a   Blanco, J L ^a   Miro J M ^a   Pumarola, T ^a   Gatell, J M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CHRONICITY; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG SENSITIVITY; FEMALE; GENOTYPE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NONHUMAN; PATIENT COMPLIANCE; PHENOTYPE; PRIORITY JOURNAL; STRUCTURED TREATMENT INTERRUPTION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; RISK FACTORS; SELECTION (GENETICS);

EID: 24644473517     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/432881     Document Type: Article

References (24)

1. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-9.
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
3. Finzi D, Blankson J, Siliciano JD et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-7.
4. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727-8.
5. Martinez E, Mocroft A, García-Viejo M, et al. A prospective cohort study on the risk for lipodystrophy in HIV-1 infected patients treated with protease inhibitor-containing regimens. Lancet 2001; 357:592-8.
6. Plana M, Garcia F, Gallart MT, Miro JM, Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after one year of HAART in very early HIV-1 disease. Lancet 1998; 352:1194-5.
7. Garcia F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999; 13:F79-86.
8. Carcelain G, Tubiana R, Samri A, et al. Transient mobilization of human immunodeciency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection. J Virol 2001; 75:234-41.
9. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292:251-65.
10. Martinez-Picado J, Morales-Lopetegui K, Wrinb T, et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 2002; 16:895-9.
11. Metzner KJ, Bonhoeffer S, Fischer M, et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J Infect Dis 2003; 188:1433-43.
12. Papasavvas E, Grant RM, Sun J, et al. Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients. AIDS 2003; 17:2337-43.
13. Schweighardt B, Ortiz GM, Grant RM, et al. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS 2002; 16:2342-4.
14. Dybul M, Nies-Kraske E, Daucher M, et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 2003; 188:388-96.
15. Yerly S, Fagard C, Gunthard HF, Hirschel B, Perrin L. Drug resistance mutations during structured treatment interruptions. Antivir Ther 2003; 8:411-5.
16. Ananworanich J, Nuesch R, Le Braz M, et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17:F33-7.
17. García F, Plana M, Ortiz GM, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001; 15:F29-40.
18. Garcia F, Plana M, Arnedo M, et al. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS 2003; 17:43-51.
19. Fagard C, Oxenius A, Gunthard H, et al. A prospective trial of structured treatment interruptions in HIV infection. Arch Intern Med 2003; 163:1220-6.
20. García F, Plana M, Arnedo M, et al. Effect of mycophenolate mophetil on immune response and on plasma and lymphatic tissue viral load during and after interruption of HAART in chronic HIV-1 infected patients: a pilot randomized study. J Acquir Immune Defic Syndr 2004; 36:823-30.
21. Garcia F, Lejeune M, Climent N, et al. Therapeutic immunization with dendritic cells loaded with inactivated autologous HIV-1 in chronic HIV-1 infected patients: a pilot randomized trial. J Infect Dis 2005; 191:1680-5.
22. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-80.
23. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837-46.
24. Devereux HL, Emery VC, Johnson MA, Loveday C. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 2001; 65:218-24.